Carla Leal Moreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carla Leal Moreira has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- António Cabrita
Centro Hospitalar Universitário do Porto, Portugal
4 shared publications - Ana Castro
Centro Hospitalar do Porto, Hospital de Santo António, Departamente de Nefrologia, Porto, Portugal
2 shared publications António Castro Henriques
Nephrology Department, Centro Hospitalar Universitário do Porto, Hospital Geral de Santo António, Porto, Portugal
2 shared publicationsJoana Rocha
Nephrology Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal
2 shared publicationsLeonídio Dias
Nephrology Department, Centro Hospitalar Universitário do Porto, Hospital Geral de Santo António, Porto, Portugal
2 shared publications- Ana Rocha
Unidade Corino de Andrade, Porto, Portugal
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2021 (1)
Nephrotic Syndrome as a Cause of Transient Clinical Hypothyroidism
Nephrotic syndrome may trigger the onset of hypothyroidism, promoting massive urinary protein losses including thyroxine (T4) and triiodothyronine (T3) along with their binding proteins. At an early stage, a clinical and biochemical euthyroid state is expected. However, in patients with prolonged and severe proteinuria, especially with concomitant low thyroid reserve, urinary losses of free and protein‐bound thyroid hormones are sufficiently pronounced to induce a subclinical or overt hypothyroidism. Despite its high prevalence in clinical practice, the literature lacks case reports of newly diagnosed clinical hypothyroidism due to NS in adults, making this condition under‐recognized. We report a case of a 23‐year‐old man with previous normal thyroid function who developed overt hypothyroidism due to a severe nephrotic syndrome, requiring supplementation with levothyroxine (LT). After the patient had undergone bilateral nephrectomy, treatment with LT was discontinued and thyroid function normalized.
- 1 January 2021
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2021 (1)
Open AccessNephrotic Syndrome as a Cause of Transient Clinical Hypothyroidism
Nephrotic syndrome may trigger the onset of hypothyroidism, promoting massive urinary protein losses including thyroxine (T4) and triiodothyronine (T3) along with their binding proteins. At an early stage, a clinical and biochemical euthyroid state is expected. However, in patients with prolonged and severe proteinuria, especially with concomitant low thyroid reserve, urinary losses of free and protein‐bound thyroid hormones are sufficiently pronounced to induce a subclinical or overt hypothyroidism. Despite its high prevalence in clinical practice, the literature lacks case reports of newly diagnosed clinical hypothyroidism due to NS in adults, making this condition under‐recognized. We report a case of a 23‐year‐old man with previous normal thyroid function who developed overt hypothyroidism due to a severe nephrotic syndrome, requiring supplementation with levothyroxine (LT). After the patient had undergone bilateral nephrectomy, treatment with LT was discontinued and thyroid function normalized.
- 7 October 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (7) , 1615-1624
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience
Background.: Experience with sequential hematopoietic stem cell transplant (HSCT) and kidney transplant (KT) is limited. Methods.: We conducted a retrospective observational study of adult patients who underwent both HSCT and KT at our center, with a median follow-up of 11 y. Results.: In our 54 patients cohort (94% autologous HSCT), 36 (67%) patients received HSCT first followed by KT, while 18 (33%) received KT before HSCT. In both groups, AL amyloidosis represented 50% of hematologic diagnosis. Only 4 patients expired due to hematologic disease relapse (2 patients in each group) and only 3 allografts were lost due to hematologic disease recurrence (HSCT first n = 1 and KT first n = 2). Overall 1, 5, and 10 y death-censored graft survival rates were 94%, 94%, and 94%, respectively, for the HSCT first group and 89%, 89%, and 75%, respectively, for the KT first group. Overall 1, 5, and 10 y patients survival rates were 100%, 97% and 90%, respectively, for the HSCT first group and 100%, 76%, and 63%, respectively, for the KT first group. Conclusions.: Our study supports safety of sequential KT and HSCT, with improved overall patient survival compared to recipients of HSCT remaining on dialysis and good long-term kidney allograft outcome.
- 7 October 2020
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (7) , 1615-1624
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience
Background.: Experience with sequential hematopoietic stem cell transplant (HSCT) and kidney transplant (KT) is limited. Methods.: We conducted a retrospective observational study of adult patients who underwent both HSCT and KT at our center, with a median follow-up of 11 y. Results.: In our 54 patients cohort (94% autologous HSCT), 36 (67%) patients received HSCT first followed by KT, while 18 (33%) received KT before HSCT. In both groups, AL amyloidosis represented 50% of hematologic diagnosis. Only 4 patients expired due to hematologic disease relapse (2 patients in each group) and only 3 allografts were lost due to hematologic disease recurrence (HSCT first n = 1 and KT first n = 2). Overall 1, 5, and 10 y death-censored graft survival rates were 94%, 94%, and 94%, respectively, for the HSCT first group and 89%, 89%, and 75%, respectively, for the KT first group. Overall 1, 5, and 10 y patients survival rates were 100%, 97% and 90%, respectively, for the HSCT first group and 100%, 76%, and 63%, respectively, for the KT first group. Conclusions.: Our study supports safety of sequential KT and HSCT, with improved overall patient survival compared to recipients of HSCT remaining on dialysis and good long-term kidney allograft outcome.
- Open Access
- 1 March 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (1) , 31-37
Does Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function?
Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function.
- 1 March 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (1) , 31-37
Open AccessDoes Cystatin C have a role as metabolic surrogate in peritoneal dialysis beyond its association with residual renal function?
Introduction: It has been suggested that cystatin C levels are modified by obesity and inflammation. Furthermore, cystatin C has been associated with cardiovascular events and mortality outcomes. Aim: To study the association of cystatin C with the metabolic profile and cardiovascular disease of peritoneal dialysis patients. Methods: Data collected included clinical, laboratorial, and multifrequency bioimpedance assessment of 52 stable peritoneal dialysis patients. Minimal residual renal function was defined as > 2mL/min/1.73m2. Results: Serum cystatin C was not significantly associated with peritoneal or urinary cystatin C excretion. Negative correlation of cystatin C with normalized protein catabolic rate (rho -0.33, p = 0.02) and a trend towards positive correlation with relative body fat (rho 0.27, p = 0.05) were not independent from residual renal function. Cystatin C was not significantly associated with cardiovascular disease (p = 0.28), nor with glycated hemoglobin (p = 0.19) or c-reactive protein (p = 0.56). In the multivariate model, both age and diabetes were the strongest predictors of cardiovascular disease (odds ratio 1.09, p = 0.029 and odds ratio 29.95, p = 0.016, respectively), while relative body fat was negatively associated with cardiovascular disease (p = 0.038); neither cystatin C (p = 0.096) nor minimal residual renal function (p = 0.756) reached a significant association with cardiovascular disease. Conclusions: In this group of peritoneal dialysis patients, cystatin C did not correlate with the metabolic or inflammatory status, nor cardiovascular disease, after adjustment for residual renal function.
- 1 February 2019
- Published by Wiley in Hemodialysis International
- Vol. 23 (3) , E90-E92
Stenosis and thrombosis—unveiled complications of buttonhole cannulation
The vascular access is the mainstay of hemodialysis. Arteriovenous fistula has been prioritized as the first choice of long‐term vascular access for its inferior rate of complications and improved patient survival. Rope ladder and buttonhole venipuncture are the most common techniques for arteriovenous fistulae cannulation. Much of the concern regarding buttonhole cannulation is the increased risk for potentially severe systemic infections. Increased risk for stenosis and thrombosis has been addressed but not confirmed. We discuss two cases of stenosis and thrombosis related to buttonhole puncture which heralded angiography intervention, raising awareness for the demand of close surveillance of arteriovenous fistulae when using buttonhole cannulation.
- 1 February 2019
- Published by Wiley in Hemodialysis International
- Vol. 23 (3) , E90-E92
Stenosis and thrombosis—unveiled complications of buttonhole cannulation
The vascular access is the mainstay of hemodialysis. Arteriovenous fistula has been prioritized as the first choice of long‐term vascular access for its inferior rate of complications and improved patient survival. Rope ladder and buttonhole venipuncture are the most common techniques for arteriovenous fistulae cannulation. Much of the concern regarding buttonhole cannulation is the increased risk for potentially severe systemic infections. Increased risk for stenosis and thrombosis has been addressed but not confirmed. We discuss two cases of stenosis and thrombosis related to buttonhole puncture which heralded angiography intervention, raising awareness for the demand of close surveillance of arteriovenous fistulae when using buttonhole cannulation.
- Open Access
- 1 January 2019
- Published by Elsevier in Nefrología (English Edition)
- Vol. 39 (1) , 106-107
Adenovirus infection—A rare cause of interstitial nephritis in kidney transplant
- 1 January 2019
- Published by Elsevier in Nefrología (English Edition)
- Vol. 39 (1) , 106-107
Open AccessAdenovirus infection—A rare cause of interstitial nephritis in kidney transplant
- Open Access
- 7 August 2018
- Published by Elsevier in Nefrología
- Vol. 39 (1) , 106-107
Adenovirus infection—A rare cause of interstitial nephritis in kidney transplant
- 7 August 2018
- Published by Elsevier in Nefrología
- Vol. 39 (1) , 106-107
Open AccessAdenovirus infection—A rare cause of interstitial nephritis in kidney transplant
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 117-118
The ever-growing understanding of transthyretin amyloidosis nephropathy
(2017). The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid: Vol. 24, PROCEEDINGS OF THE XVth INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS, pp. 117-118.
- 16 March 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (sup1) , 117-118
The ever-growing understanding of transthyretin amyloidosis nephropathy
(2017). The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid: Vol. 24, PROCEEDINGS OF THE XVth INTERNATIONAL SYMPOSIUM ON AMYLOIDOSIS, pp. 117-118.